Ironwood Pharmaceuticals (IRWD) Insider Trading & Ownership $2.30 -1.42 (-38.17%) Closing price 01/30/2025 04:00 PM EasternExtended Trading$2.34 +0.04 (+1.52%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ironwood Pharmaceuticals (NASDAQ:IRWD) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage12.90%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$160,419.92Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$4.70 M Get IRWD Insider Trade Alerts Want to know when executives and insiders are buying or selling Ironwood Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address IRWD Insider Buying and Selling by Quarter Ironwood Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/18/2024Andrew DavisSVPSell5,360$4.08$21,868.80 11/18/2024Sravan Kumar EmanyCFOSell11,001$4.08$44,884.08 8/12/2024Minardo JohnInsiderSell9,910$4.27$42,315.70 6/10/2024Julie MchughDirectorSell22,766$6.29$143,198.14 6/6/2024Catherine MoukheibirDirectorSell44,426$6.36$282,549.36 3/6/2024Jon R DuaneDirectorBuy6,920$8.70$60,204.00 3/4/2024Sravan Kumar EmanyCFOBuy10,684$9.38$100,215.92 2/12/2024Andrew DavisSVPSell9,846$15.24$150,053.04 2/12/2024Michael ShetzlineCMOSell38,618$15.24$588,538.32 2/12/2024Minardo JohnInsiderSell47,380$15.24$722,071.20 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 2/12/2024Thomas A MccourtCEOSell177,164$15.24$2,699,979.36 (Data available from 1/1/2013 forward) IRWD Insider Trading Activity - Frequently Asked Questions Who is on Ironwood Pharmaceuticals's Insider Roster? The list of insiders at Ironwood Pharmaceuticals includes Andrew Davis, Catherine Moukheibir, Jason Rickard, Jon R Duane, Julie Mchugh, Mark G Currie, Marla L Kessler, Michael Shetzline, Minardo John, Ronald Silver, Sravan Kumar Emany, and Thomas A Mccourt. Learn more on insiders at IRWD. What percentage of Ironwood Pharmaceuticals stock is owned by insiders? 12.90% of Ironwood Pharmaceuticals stock is owned by insiders. Learn more on IRWD's insider holdings. Which Ironwood Pharmaceuticals insiders have been buying company stock? The following insiders have purchased IRWD shares in the last 24 months: Jon R Duane ($60,204.00), and Sravan Kumar Emany ($400,334.96). How much insider buying is happening at Ironwood Pharmaceuticals? Insiders have purchased a total of 53,676 IRWD shares in the last 24 months for a total of $460,538.96 bought. Which Ironwood Pharmaceuticals insiders have been selling company stock? The following insiders have sold IRWD shares in the last 24 months: Andrew Davis ($191,900.75), Catherine Moukheibir ($282,549.36), Jason Rickard ($191,071.86), Julie Mchugh ($143,198.14), Michael Shetzline ($696,568.20), Minardo John ($764,386.90), Ronald Silver ($33,419.89), Sravan Kumar Emany ($44,884.08), and Thomas A Mccourt ($4,422,817.91). How much insider selling is happening at Ironwood Pharmaceuticals? Insiders have sold a total of 555,034 Ironwood Pharmaceuticals shares in the last 24 months for a total of $6,770,797.09 sold. Ironwood Pharmaceuticals Key ExecutivesMr. Thomas A. McCourt (Age 67)CEO & Director Compensation: $1.61MMr. Sravan Kumar Emany (Age 46)Senior VP, Principal Financial Officer & CFO Compensation: $913.88k1 recent tradesMr. John Minardo (Age 48)Senior VP, Chief Legal Officer & Secretary Compensation: $814.41kDr. Michael Shetzline M.D. (Age 65)Ph.D., Chief Medical Officer, Senior VP and Head of Research & Drug Development Compensation: $860.45kMr. Andrew Davis (Age 37)Senior VP & Chief Business Officer Compensation: $824.36k1 recent tradesMr. Ronald Silver (Age 41)Corporate Controller & Principal Accounting Officer Mr. Marcel MoulaisonVice President of Technical OperationsGreg MartiniVice President of Strategic Finance & Investor RelationsMs. Beth CalitriHead of Corporate Communications & Media RelationsMr. Mike NanfitoVice President of Sales & Sales Excellence More Insider Trading Tools from MarketBeat Related Companies Ligand Pharmaceuticals Insider Trades Geron Insider Trades MannKind Insider Trades BioCryst Pharmaceuticals Insider Trades Dynavax Technologies Insider Trades Celldex Therapeutics Insider Trades Novavax Insider Trades Innoviva Insider Trades Myriad Genetics Insider Trades OPKO Health Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for Investors This page (NASDAQ:IRWD) was last updated on 1/31/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
